Quercetin’s Mechanistic Role in Suppressing Ferroptosis in Wilson’s Disease Liver Injury

Study Background and Research Question

Wilson’s disease (WD) is an autosomal recessive disorder marked by copper accumulation, primarily in the liver, resulting in progressive hepatic injury ranging from steatosis to cirrhosis. While copper toxicity is a known driver, recent attention focuses on ferroptosis—a regulated, iron-dependent form of cell death characterized by lipid peroxidation and mitochondrial dysfunction—as a critical process in WD pathogenesis. However, the precise contribution of ferroptosis to WD-related liver injury, and whether pharmacological inhibition could yield therapeutic benefit, remains insufficiently characterized. The current reference study addresses these questions, interrogating the efficacy and mechanisms of quercetin, a dietary flavonoid known for its PI3K inhibitor and anti-inflammatory properties, in experimental WD models.

Key Innovation from the Reference Study

The central innovation of this work lies in its mechanistic dissection of how quercetin mitigates WD liver injury by directly suppressing ferroptosis. Unlike prior research broadly linking flavonoids to antioxidant effects, this study identifies the ACSL4/LPCAT3/ALOX15 signaling axis as a direct molecular target of quercetin. The authors not only show that quercetin binds to and inhibits ACSL4 activity but also demonstrate reversal of pathological lipidomic signatures and mitochondrial dysfunction in vivo and in vitro. This multi-level approach integrates molecular docking, lipidomics, and functional genetics, providing compelling evidence for quercetin’s multi-targeted, pathway-specific action in ferroptotic regulation.

Methods and Experimental Design Insights

The study employs both Atp7b-deficient (Atp7b^tx-J/J) mouse models and HepG2 cell cultures to recapitulate WD pathophysiology. Hepatic injury was evaluated via histopathology, transmission electron microscopy (TEM), and serum biochemistry. To assess ferroptosis, the authors measured hepatic iron content, malondialdehyde (MDA) levels, reactive oxygen species (ROS), glutathione (GSH) metabolism, and mitochondrial membrane potential (using JC-1 staining). Lipidomics approaches were applied to analyze changes in glycerolipid and glycerophospholipid profiles. Mechanistic validation involved ACSL4 overexpression, with molecular docking, molecular dynamics, cellular thermal shift assays, and surface plasmon resonance confirming direct quercetin-ACSL4 interaction. Downstream effects on the LPCAT3/ALOX15 axis were explored by RT-qPCR, Western blotting, and immunofluorescence.

Protocol Parameters

• Animal model dosing: Quercetin was administered to Atp7b^tx-J/J mice with dosing and duration tailored to match hepatic copper accumulation timelines; refer to the original study for precise regimens.
• Ferroptosis assessment: Use of JC-1 probe for mitochondrial membrane potential, iron quantification assays, and lipid peroxidation (MDA, 4-HNE) as primary endpoints.
• Lipidomics: Employ shotgun lipidomics or LC–MS/MS platforms to quantify glycerolipid/glycerophospholipid alterations post-treatment.
• Mechanistic validation: ACSL4 overexpression or knockdown in cell models, with subsequent assessment of ferroptosis markers and direct compound-protein binding (thermal shift or SPR assays).

Core Findings and Why They Matter

Quercetin administration led to marked improvement in hepatic histopathology, with reductions in steatosis, necrosis, and inflammatory infiltration. Serum markers of liver injury (ALT, AST) were significantly lowered. Importantly, quercetin suppressed hepatic iron overload, decreased ROS and lipid peroxidation, and restored mitochondrial membrane potential—collectively, hallmarks of ferroptosis inhibition. Lipidomics revealed that quercetin reversed the WD-associated accumulation of glycerolipids and restored glycerophospholipid homeostasis. Mechanistically, quercetin was shown to directly bind to ACSL4, inhibiting the ACSL4/LPCAT3/ALOX15 signaling cascade, which is central to phospholipid peroxidation and ferroptosis. ACSL4 overexpression abrogated the protective effect of quercetin, confirming pathway specificity. These findings position quercetin as a multi-target apoptosis inducer via the mitochondrial pathway, and as a potent modulator of cell cycle regulation and caspase activation in ferroptosis-related liver injury (see study).

Comparison with Existing Internal Articles

Several internal articles highlight quercetin’s roles in cell viability, PI3K inhibition, and apoptosis induction. For instance, "Quercetin (SKU N1841): Reliable PI3K Inhibitor for Cell Assays" discusses its application in cytotoxicity workflows, underscoring mechanistic validation as a PI3K inhibitor and mitochondrial apoptosis modulator. The present reference study extends these findings by establishing direct actions on the ferroptotic pathway, specifically implicating ACSL4 as a new molecular target. Similarly, the article "Quercetin as a PI3K Inhibitor: Experimental Workflows & Tips" notes quercetin’s benchmark status in both cancer research and liver disease models, while the current study provides novel lipidomics and protein interaction data supporting its efficacy as a ferroptosis suppressor. Notably, these resources converge on quercetin’s utility in mechanistically dissecting apoptosis, anti-inflammatory responses, and now ferroptosis for translational research.

Limitations and Transferability

Despite the robust combination of in vivo, in vitro, and molecular approaches, several limitations should be considered. First, murine WD models recapitulate but do not fully replace human disease complexity, particularly regarding chronicity and comorbidities. Second, while direct binding to ACSL4 was validated, the potential for quercetin to interact with other lipid-metabolic or cell death regulators (such as GPX4 or NF-κB) cannot be excluded and warrants further investigation. Dosing regimens and compound pharmacokinetics in mice may not directly extrapolate to human or other model systems, and quercetin’s pleiotropic actions require careful interpretation in multi-pathway contexts. Transferability to other ferroptosis-related hepatic or non-hepatic injuries should be considered speculative unless supported by additional studies. The cross-domain application of these findings—for example, to cancer research or neurodegeneration—should be explored with protocol adjustments and further mechanistic validation.

Research Support Resources

Researchers interested in modeling ferroptosis, mitochondrial apoptosis, or PI3K pathway inhibition can leverage Quercetin (SKU N1841) from APExBIO, which is validated in multiple cell-based and animal studies. For detailed protocol troubleshooting or assay optimization, the above-cited internal articles offer workflow guidance. As always, ensure experimental design aligns with the specific endpoints and signaling pathways relevant to your disease model.